ARK Investment Cuts Stake in 10x Genomics

Genomics company sees shares sold by major investor

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

ARK Investment Management LLC, a prominent investment firm, has reduced its position in 10x Genomics (NASDAQ:TXG) by 14.4% during the third quarter, according to a recent SEC filing. The fund now owns 11,887,396 shares of the company's stock, down from 13,892,103 shares previously.

Why it matters

10x Genomics is a leading provider of advanced genomic analysis solutions, and ARK Investment's stake in the company is significant. The reduction in their position could signal a shift in investor sentiment or portfolio rebalancing, which could impact the stock price and market perception of the company.

The details

According to the SEC filing, ARK Investment sold 2,004,707 shares of 10x Genomics during the third quarter. The fund now owns 9.55% of the company's outstanding shares, down from 11.15% previously. 10x Genomics is a Pleasanton, California-based biotechnology company that specializes in single-cell sequencing and spatial genomics technologies.

  • ARK Investment filed the 13F report detailing the stake reduction on March 5, 2026.

The players

ARK Investment Management LLC

A prominent investment management firm that focuses on disruptive innovation and technology-driven companies.

10x Genomics

A biotechnology company that develops advanced genomic analysis solutions, including single-cell sequencing and spatial genomics technologies.

Got photos? Submit your photos here. ›

The takeaway

The reduction in ARK Investment's stake in 10x Genomics could signal a shift in investor sentiment or portfolio rebalancing, which may impact the stock price and market perception of the company. However, 10x Genomics remains a leading player in the genomics space, and its long-term prospects will depend on its ability to continue innovating and driving adoption of its technologies.